Longitudinal Study Highlights Evolving Role of Medical Science Liaisons with Thought Leaders and Product D... ( CHAPEL HILL N.C. March 1 2013 /PR...)

Longitudinal Study Highlights Evolving Role of Medical Science Liaisons with Thought Leaders and Product Development

Date:3/1/2013

CHAPEL HILL, N.C., March 1, 2013 /PRNewswire/ -- While medical science liaisons have been around for more than 40 years, the role and activities of these medical specialists have grown quickly over the last decade. The pharmaceutical industry has long relied on medical science liaisons to forge relationships with key opinion leaders (KOLs) who can provide critical insights into the market and competition.

But the changing regulatory and access environment has altered the landscape for creating and maintaining KOL and physician relationships.

To help organizations navigate this new KOL landscape, research and consulting leader Best Practices LLC published a MSL-focused report that highlights their key pre- and post-launch activities, and service frequencies. The 78-page report presents 2011 data compared to 2009 on an array of critical activities that provide insights into how MSLs can build strong, productive relationships with KOLs and physicians.

"Roles, Resourcing and Management of Medical Science Liaisons" provides MSL leaders with key metrics to help them create and maintain an effective MSL group. The comparative structure of the report (2011 data vs. 2009 data) also opens a window to emerging trends that will enable leaders in medical affairs – the group where MSL operations are typically housed - to set a clear direction for their MSL group going forward.

For instance, the study shows companies in 2011 were having managers oversee a greater number of MSLs than they did in 2009. In 2011, 57 percent of respondents preferred to have one manager overseeing 7-10 specialists. In 2009, the preferred span-of-control was one manger to up to six specialists (47 percent).

The key topics covered in this report include:

SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. New Study Shows Cannabis Effects on Driving Skills
2. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
3. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
4. MD+DI, the Global MedTech Authority, Publishes One-of-a-Kind Study with ITG Market Research on the Medical Device Outsourcing Landscape
5. New Direct-to-Consumer Prescription Delivery Channel Mitigates Risk of Medication Non-Adherence Highlighted in JAMA Internal Medicine Study
6. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
7. Study Shows Medicare Savings When Local Pharmacies Fill 90-Day Prescriptions
8. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
9. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...

(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue: ... Optical Coherence Tomography (OCT) ... OBJECTIVES BCC,s ... offer synopsis of the current and future ...

(Date:5/21/2013)... Fla. , May 21, 2013 Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...

[0] Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...

... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...

Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4

NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients

(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...

(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...

(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...

(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3

[0] Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis [0] GW launches center to address health disparities in the Latino immigrant community [0] Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants

... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...

... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...

... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...

... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...

... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...

... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...

Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2 Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3 Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2 Health News:Louise McCormick Joins Heska's Board of Directors 2 Health News:Louise McCormick Joins Heska's Board of Directors 3

Boston Scientific to Participate in JP Morgan Health Care Conference Treatment with NAC is associated with better outcomes for children with liver failure Combo Therapy Cuts Prostate Cancer Death Rates Smart Balance Announces Conversion of Convertible Preferred Stock Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008 Louise McCormick Joins Heska's Board of Directors

... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...

... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...

Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...

Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....

Medicine Products:

CritSpin Microhematocrit Centrifuge StarLux Pulsed Light and Laser System Silicone Foley Silicone Universal Drainage Stents